Evaluating blood clotting in patients with liver cirrhosis and cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on assessing hemostasis in patients with decompensated liver cirrhosis using novel hemostatic assays. It aims to understand the delicate balance of bleeding and thrombosis in these patients, who are at risk due to their condition. By comparing the hemostatic profiles of patients with healthy controls, the study seeks to identify effective methods for evaluating hemostasis in this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with decompensated liver cirrhosis
* 18 years or older.
* Healthy individuals 18 years or older will serve as controls.

Exclusion Criteria:

* • Extrahepatic malignancy or recurrence of such within the last year.

  * Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
  * Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
  * Previous liver transplantation.
  * Transfusions the last 7 days.
  * Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.

Where it's running

• Karolinska University Hospital
  Stockholm, Huddinge, Sweden Recruiting

Study contacts

• Principal investigator: Maria Magnusson, MD, PhD — Region Stockholm, Karolinska Institute
• Study coordinator: Sanna Norén, MD, PhDstudent
• Email: sanna.noren@regionstockholm.se
• Phone: +46703131799

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single vs repeated cycles of G-CSF and darbepoetin in early decompensated cirrhosis

  This trial tests whether giving multiple rounds of G-CSF plus darbepoetin helps people with early decompensated cirrhosis more than a single round or standard care.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07002827

• Atorvastatin plus beta-blockers for people with decompensated cirrhosis

  This pilot Phase 2 trial will test whether adding atorvastatin 20 mg to standard non‑selective beta‑blocker therapy helps adults with decompensated cirrhosis avoid complications over 12 months.

  Recruiting Phase 2 CAMC Health System · Charleston, West Virginia · NCT06764966

• LEOPARD: Predicting liver transplant dropout with AI in European patients

  This project tests new AI-based models to predict which liver transplant candidates are at highest risk of dropout or death while on the waitlist.

  Recruiting at 4 sites Assistance Publique - Hôpitaux de Paris · Ghent, Belgium and 7 other locations · NCT06723275

• Collecting data to improve liver transplantation predictions

  This study is trying to use AI to better predict which liver transplant candidates are at risk of dropping out of the waitlist, so that more people can get fair access to transplants across Europe.

  Recruiting at 53 sites Assistance Publique - Hôpitaux de Paris · Vienna and 52 other locations · NCT06675604

• TIPS treatment for decompensated liver cirrhosis

  Collecting clinical data and blood samples from adults with decompensated liver cirrhosis who receive a TIPS to try to improve how doctors choose who should get the procedure.

  Recruiting Hannover Medical School · Hanover, Lower Saxony · NCT04801290

• Allopurinol to prevent complications in decompensated liver cirrhosis

  This trial tests whether allopurinol can reduce complications in adults with decompensated cirrhosis.

  Recruiting at 2 sites Phase 4 Bangladesh Medical University · Dhaka, Shahbagh and 1 other locations · NCT07800598

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.